Key Takeaways
- HPPC powers 31% growth, but textiles drag: The Home, Personal Care & Performance Chemicals division surged 31% YoY on volume, while Textile Specialties fell 13% on soft end-market demand, creating a two-speed quarter.
- Ethoxylation is maxed out: Capacity is at 100% utilization, constraining Tristar to just 5% growth and forcing a capacity expansion that won't deliver its first ramp-up for five months.
- Exports hit an all-time high: At nearly 23% of revenue, exports are the highest ever, driven by US food processing, home care and agro demand.
- FY24 guidance held, FY25 ambition set: Management stuck to 10-12% growth for FY24 and laid down a mid-teen (15%) top-line target for next year, with new CAPEX revenues arriving late in FY25.
- What to watch next quarter: Whether the textile demand recovery actually materializes, the pace of the Dahej expansion build, and if gross margins hold at the promised 30%.
HPPC: The Growth Engine
- Volume-led surge: The 31% YoY jump was overwhelmingly volume-driven, with volumes up 30-35%+, not a pricing story.
- Institutional Chemicals fastest: Institutional Cleaning grew the fastest in percentage terms, followed by non-agro Specialty Surfactants, though management declined to give segment-level revenue figures.
- New products landing well: CAPB and Cocodiethanolamide, two newly introduced products, are seeing good demand and can deliver 1,000 tons+ of sales this year itself.
- Biosurfactants scaling 10x: A 200-ton-plus per annum capacity is being established, up from the current 3 tons per month, targeting a 10x expansion.
- Silicone Surfactants tripling: Capacity is being tripled to capture share from a >1,000 ton per annum potential in the agro market, with products also ready for cosmetics, textiles and coatings.
Menezes: "The run-of-the-mill products Ethoxylates most Ethoxylaters make, but all these different kinds of additions are what we are doing. One of the latest ones is, as I said, Silicone surfactant which very few people do, because the reaction is quite a tough reaction, and it contains Hydrosilylation also, which is also a very controlled kind of reaction."
Capacity Constraints & The Dahej Build
- Ethoxylation fully utilized: Capacity is practically 100% used, which constrained Tristar to only 5% YoY growth despite rising volumes, because there is simply no room left.
- Unitop picking up the slack: Unitop grew 25% YoY as some products were shifted into its facilities to relieve pressure on Tristar.
- First relief in five months: The first ramp-up of new Ethoxylation capacity is expected within five months, with full commissioning of Dahej projects targeted by Q3 FY25.
- Tristar distillation add: A distillation capacity addition for Tristar is also underway and should take 4-5 months.
- Rossari facility still has headroom: The main Rossari facility is at 55-60% utilization because formulation capacity, which typically runs at 60-70%, still has room to absorb volume.
- CAPEX revenues back-end loaded: Most CAPEX-linked revenues will come only by the end of FY25, with some arriving in the last quarter of next year, and full ramp-up in FY26.
- Debt mix set: The expansion will be funded with a 75:25 debt-to-internal-accruals mix, with bank discussions ongoing.
Menezes: "Practically, we are using 100% capacity in ethoxylation."
Textile Specialties: The Drag
- Revenue down 13%, but volumes held: The division saw a revenue drop driven by soft underlying demand in textiles, though volumes remained steady, indicating pricing pressure rather than demand destruction.
- Post-COVID hangover: Demand slackened because American consumers, flush with government stimulus during COVID, bought heavily into towels, bed sheets and linens, and the supply chain overstocking from 2021-22 is only now gradually unwinding.
- No import threat: Management sees no big imports coming into India, so the weakness is purely a demand-side issue, not a competitive one.
- Recovery bet for next fiscal: Management is optimistic about a demand uptick in both domestic and export markets in the next fiscal year, expecting a positive turnaround.
- Refocusing the portfolio: New initiatives include a full coating range for technical textiles, silicone-plus-wax lubricants for yarn and threads (launching in 3-4 months), and the RENEWA green chemistry process for terry towels.
Chari: "In Textile chemicals, we don't see any big imports coming into India. The demand is not so strong. What had happened is in COVID, there was a big demand because American consumers were given extra money by the government and the focus was on hygiene and hence there was lot of disposables taking place every month and they were buying a lot of towels and bed sheets and linens. Now, that has slackened off."
Exports & Customer Concentration
- Highest-ever export share: Exports reached nearly 23% of revenue, an all-time high, driven by the US market in food processing surfactants, home care and agro.
- Reliance milestone: In October, Rossari was the highest Ethylene Oxide consumer for Reliance in India, a signal of scale in its core raw material sourcing.
- Export growth to outpace domestic: Management expects export turnover to grow at 12-14%, versus 10% for domestic, with total turnover forecast at 10-12%.
Chari: "Exports now are nearly 23%, which is the highest ever in our history."
Margins & Profitability
- Gross margin improving sequentially: Gross margin saw a sequential improvement, and management expects to maintain 30% in the next quarter.
- Raw material stability helping: EBITDA growth was supported by a stable raw material situation combined with revenue growth.
- Q4 EBITDA similar to Q3: Management guided that Q4 EBITDA margin will be similar to Q3, with a sustainable range of 13.67-14.12%.
- Absolute EBITDA growth mid-teens: Absolute EBITDA is expected to grow at roughly the same rate as the top line, in the mid-teens.
- No write-off risk: Despite falling raw material and finished goods prices, there have been no write-offs related to expiry of goods in TSC or HPPC, because volumes remain intact, an unusual outcome in specialty chemicals.
Product Pipeline & New Initiatives
- PEG Powders: A high-CAPEX project to manufacture PEG in powder form for the first time (currently only liquid and flake), with the product ready in six months.
- Sorbitan Esters: A 10x increase is planned, with the company stopping external purchases and moving to in-house production.
- Phenoxy Propanol: A next-generation antimicrobial for personal care that management intends to pursue in a big way.
- Ester Quartz: A vegetable-based softener (not animal origin) that has seen good success in some countries and is being pushed hard worldwide, including in the India retail market.
- Water-less dyeing: A new concept being trialed for textiles using less water in the dyeing process.
- ONGC breakthrough: Rossari secured its first large order from ONGC in the oil and gas industry, opening a new end-market.
- No new verticals: Management will stick to its four existing chemistries and add new products and molecules within those, rather than branching into new verticals.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 revenue growth | 10-12% growth maintained | FY24 |
| FY25 revenue growth | Mid-teen (15%) top-line growth | FY25 |
| Dahej expansion commissioning | Phased completion of both projects | Q3 FY25 |
| First Ethoxylation capacity ramp-up | New capacity online | Within 5 months |
| Tristar distillation capacity | Addition complete | 4-5 months |
| CAPEX revenue contribution | Most revenues begin; full ramp-up in FY26 | Late FY25 / FY26 |
| Q4 FY24 EBITDA margin | Similar to Q3; sustainable range 13.67-14.12% | Q4 FY24 |
| Gross margin | Maintain 30% | Next quarter |
| PEG Powders product readiness | Product ready | 6 months |
| Lubricants product line launch | Launched in India | 3-4 months |
| CAPEX funding mix | 75:25 debt-to-internal-accruals | Ongoing |
| Asset turn on new CAPEX | Average around 4-5x | FY25/FY26 |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated revenue | ₹463.8 cr, +19% YoY |
| EBITDA | ₹63.7 cr, +18% YoY |
| EBITDA margin | 13.7% |
| PAT | ₹34.4 cr, +34% YoY |
| Gross margin | 30%, expected to be maintained |
| HPPC division revenue growth | +31% YoY, volume-driven |
| Textile Specialty division revenue growth | -13% YoY, though volumes intact |
| Animal Health division revenue growth | +22% QoQ |
| Revenue mix | HPPC 77%, Textile Specialty 18%, Animal Health 5% |
| Overall volume growth | 30%-35%+ YoY |
| Exports share | 23% of revenue, highest ever |
| Ethoxylation capacity utilization | 85%+, fully utilized across facilities |
| Overall capacity utilization | ~55%, near peak formulation levels |
| FY25 revenue growth guidance | ~15% (mid-teen) |
| FY25 EBITDA margin guidance | 13.67%-14.12% |
| Dahej expansion total CAPEX | ₹180 cr, commissioning phased through Q3 FY25 |